Global Polyclonal Antibody Market, By Type (Primary Antibody and Secondary Antibody), By Source (Rabbits, Goats, Sheep, and Others), By Application (Academic Research, Diagnostics, and Others), By End User (Academic and Research Institutes, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 1,096.9 Mn in 2023, and is expected to exhibit a CAGR of 5.9% during the forecast period (2023-2030), as highlighted in a new report published by Coherent Market Insights.
Increasing research and development activities by key market players is expected to drive the global polyclonal antibody market growth over the forecast period. For instance, in April 2021, SAB Biotherapeutics, Inc., a pharmaceutical company, conducted a Phase 2/3 trial to evaluate a new fully-human polyclonal antibody therapeutic targeted to SARS-CoV-2. The trial, ACTIV-2, is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health.
Global Polyclonal Antibody Market - Impact of Coronavirus (COVID-19) Pandemic
The COVID-19 pandemic and consequent lockdowns in various countries across the globe have impacted the financial status of businesses across all sectors, including the private healthcare sector. The pandemic hampered the entire supply chain of the healthcare industry, mainly due to strict lockdowns in several regions. The private healthcare is one such sector that was significantly impacted by the COVID-19 pandemic.
Many patients suffering from COVID-19 had a severe respiratory infection that required hospitalization and mechanical ventilation. Governments of various countries are focusing on initiatives to fight against the COVID-19 pandemic and stop the spread of the coronavirus infection by implementing various measures in the countries. Moreover, the governments of various countries have collaborated with universities around the globe to find novel treatments option for COVID-19 and its related complications. However, the COVID-19 pandemic had a negative impact on the global polyclonal antibody market. For instance, in November 2022, according to the data published by National Center for Biotechnology Information, monoclonal and polyclonal antibodies have many advantages as these reduce viral levels and the resulting damage to the lungs. Monoclonal and polyclonal antibodies enhanced symptoms in non-hospitalised covid-19 patients and allowed non-hospitalised patients to heal more rapidly. This treatment is only carried out in people who did not have immunoglobulins to SARS-CoV-2; it has also worked better on individuals/cases with higher virus levels.
Global Polyclonal Antibody Market: Key Developments
Increasing adoption of organic strategies, such as fundings, by key market players and organizations is expected to drive the global polyclonal antibody market growth over the forecast period. For instance, in June 2021, XENOTHERA, a clinical stage biotechnology companythat is developing a technological platform of glyco-humanized polyclonal antibodies, with an expertise in both genetic and immunology, received US$ 21.5 Mn funding from European Innovation Council Fund to accelerate its research and development activities for polyclonal antibody.
Browse 44 Market Data Tables and 37 Figures spread through 190 Pages and in-depth TOC on Global Polyclonal Antibody Market, By Type (Primary Antibody and Secondary Antibody), By Source (Rabbits, Goats, Sheep, and Others),B Application (Academic Research, Diagnostics, and Others), By End User (Academic and Research Institutes, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in this market, click the link below:
https://www.coherentmarketinsights.com/market-insight/polyclonal-antibody-market-4347
Key Takeaways of the Global Polyclonal Antibody Market:
- Global polyclonal antibody market is expected to exhibit a CAGR of 5.9% during the forecast period due to increasing prevalence of cancer. For instance, on January 12, 2023, according to the data published by American Cancer Society, non-hodgkin lymphoma (NHL) is one of the most common cancers in the U.S., accounting for about 4% of all cancers. Polyclonal antibody therapy is a treatment that uses polyclonal antibodies (pAbs) to target and destroy cancer cells. Polyclonal antibody therapy is used to treat a variety of cancers including leukemia, lymphoma, and solid tumors.
- Among type, primary antibody segment is estimated to hold a dominant position in the global polyclonal antibody market over the forecast period due to increasing launch of primary antibody by key market players. For instance, in October 2022, F. Hoffmann-La Roche Ltd., a pharmaceutical company, announced the launch of Anti-PRAME (EPR 20330) Rabbit primary antibody to identify PRAME protein expression in tissue samples from patients with suspected melanoma.
- The major players operating in the global polyclonal antibody market include Thermo Fisher Scientific Inc., Santa Cruz Biotechnology, Inc., GenScript, Merck KGaA, Bio-Rad Laboratories, Inc., BioLegend, Inc., GeneTex, ROCKLAND IMMUNOCHEMICALS, INC., Abcam plc., Creative Diagnostics, Crown Bioscience, Takara Bio Inc., Geno Technology Inc., IGY Immune Technologies and Life Sciences Inc., EpigenTek Group Inc., Takeda Pharmaceutical Company Limited, and SAB Biotherapeutics
